Article Text

Download PDFPDF

740 ESGO certification for advanced ovarian cancer surgery: the experience of an oncology center to aim accreditation
Free
  1. V Bernardini1,
  2. S Giulia2,
  3. DV Antonella1,
  4. G Stefano1,
  5. C Giuseppa1,
  6. G Marina2,
  7. K Sami1,
  8. P Ilaria1,
  9. A Grazia1 and
  10. B Enrico1
  1. 1Cà Foncello, Treviso, Italy
  2. 2Ospedale Padova, Padova, Italy

Abstract

Introduction/Background*The outcomes of advanced ovarian cancer surgery is related to the size of the largest residual tumor present after surgery that represents the most important prognostic factors. ESGO developed a list of quality indicators with an update in 2020 for certification of centers to ensure the best surgery for patients. These criteria include 24 complete surgeries per year in advanced stage III and IV ovarian cancer over the last 3 years. The main target is to ensure a complete resection rate of minimum require >50% to an optimal > 65%.

Methodology From 2018 the Department of Gynecology Oncology Center of Treviso Regional Hospital is trying to obtain the Esgo accreditation for the ovarian cancer.

Result(s)*Analyzing all the cases (from 2018 to 2020) we report a total of 66 high grade ovarian cancer, a complete resection rate of 73%, with a rate of primary debulking surgeries of 74%; 83% of the surgeries were performed by a certified gynecologic oncologist. The decision for any major therapeutic intervention has been taken by a multidisciplinary team in the 80% of cases. More than 95% patients had a treatment planned at a multidisciplinary team meeting (including a surgical specialist, a radiologist, a pathologist and a medical oncologist), more than 95% patients had a required pre operative workup. More than 90% of patients had a minimum required elements in pathology reports, we recorded prospectively all of the post operative complications. According to all of these aspects our center obtained a score of 32 points.

Conclusion*Actually the quality of the team work in our center has improved in the last three years. We started in 2018 with 18 cases of ovarian cancer moving up in the last two years to 24 cases. In 2020 we reported a lower rate of complete resection due to the more complex surgery for a more radical surgery to get a complete cytoreduction. We realized that since we begin to collect data for the accreditation we improved our surgical approach for the advance ovarian cancer.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.